Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug

Phase 3RentosertibPositive

AI Analysis

Summary

Insilico Medicine announced dosing of the first patient in GENESIS-IPF-3, a Phase III trial of Rentosertib (ISM001-055/INS018_055), marking the world's first Phase III trial of a generative AI-driven drug candidate. The trial is investigating the therapeutic potential of Rentosertib for idiopathic pulmonary fibrosis.

Clinical Trial Data

Phase

Phase 3

Outcome Details

First patient dosed in GENESIS-IPF-3 Phase III trial

Importance:6/10

Sentiment:

0.60

Phase 3Generative AIDrug DevelopmentFirst-in-ClassIPF

Related Companies

$SHWZ $TRAX $WHEN

Read the original article

Published by PR Newswire Biotech on September 10, 2026 12:30 AM

Read Original